38 results about "Artificial protein" patented technology

The present invention relates to a bulked yarn having a bulkiness of 10 cm < 3 > / g or more, the bulked yarn comprising a first fiber and a second fiber, the first fiber comprising an artificial protein fiber which contains an artificial protein and which can shrink after contact with water, and the second fiber having a lower shrinkage rate after contact with water than the first fiber, and the bulked yarn having a bulkiness of 10 cm < 3 > / g or more.

The present invention relates to a synthetic peptide comprising the following elements from the N-terminus to the C-terminus: a) a first cell-penetrating peptide or functional fragments or derivatives, or biologically active variants thereof and b) a second peptide with agonist activity of OR1 and OR2 receptors or functional fragments or derivatives, or biologically active variants thereof.

The present invention relates to an artificial fur and a method for manufacturing the same, and aims to provide an artificial fur which has sufficient moisture absorption performance and can reduce the energy consumption required for manufacturing. The artificial fur according to the present invention contains artificial protein fibers.

The application provides a method and system capable of end-to-end protein design and analysis verification, and can generate protein or protein complex structure and sequence according to specific requirements, and the method comprises the following steps: performing loss calculation on the three-dimensional structure of the initialized protein sequence obtained through the structure prediction algorithm independently developed by the company based on confidence, stability, target correlation; continuously improving the designed protein sequence and structure based on the Markov chain Monte Carlo algorithm or gradient regression according to the obtained loss; and putting the designed protein structure into a sequence design model to optimize the side chain, and obtaining the optimal candidate protein through screening. The method can train the model to be specific and automatic for protein design, and can generate a new artificial protein which is completely different from natural protein in structure and sequence.

Provided is a fiber-reinforced composite material that exhibits excellent characteristics in both heat resistance and impact strength regardless of the contained amount of an inorganic filler. The present invention also provides a method for advantageously producing the fiber-reinforced composite material.　This fiber-reinforced composite material comprises a thermoplastic resin, and artificial protein fibers containing an artificial protein. The fiber diameter of the artificial protein fibers is 1-30 μm and the percentage content of the artificial protein fibers is 0.5-30 mass%. This method is for producing said fiber-reinforced composite material.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector for specifically targeting a target cell and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen targeting artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Moreton vesicular disease virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Moreton vesicular disease virus envelope, provided by the invention, can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed based on mutated Moreton vesicular disease virus envelope protein is better in stability in serum, and has a good application prospect. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

Disclosed is a printing ink including a fixing agent including a peptide polymer (having a polypeptide chain), a liquid medium, and a colorant. Also disclosed is a method of manufacturing a printed matter, the method comprising: a step of forming a film containing a printing ink on a substrate by a printing process; and removing the solvent from the film to form a printed film containing the fixing agent and the coloring agent. The polypeptide chain may also include an artificial protein.

The invention belongs to the technical field of bioengineering and application thereof, and particularly relates to fucoidanase based on ancestor sequence reconstruction and application of the fucoidanase. An assumed artificial protein with endo-1, 3-fucosan activity is constructed through an ancestor sequence reconstruction strategy, so that the artificial endo-1, 3-fucosan enzyme which is completely different from a fucosan enzyme sequence of a natural source is obtained, and the amino acid sequence of the artificial endo-1, 3-fucosan enzyme is SEQ ID NO. 1. The fucoidanase can be used for degrading fucoidan from various sources in an incision manner, and under the condition of controlling the enzyme addition amount or the reaction time, the fucoidan can be quickly degraded within 10 minutes to generate fucoidan oligosaccharide with a specific structure.

The invention relates to an efficient method for synthesizing self-assembling artificial proteins (SAPs) utilizing a catalytic host-guest system. The process involves encapsulating hydrophobic probes with cyclodextrin, performing site-specific protein bioconjugation, and employing a second catalysis cycle for enhanced labeling. SAPs produced through this method are versatile and find applications in therapeutic delivery and diagnostics. The process is simplified, scalable, cost-effective, and environmentally sustainable, addressing the challenges of traditional SAP synthesis. By offering improved yield, functionality, and structural integrity, this invention advances the potential of SAPs in medical and industrial fields.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen-targeted artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Maraba virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Maraba virus envelope provided by the invention can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed on the basis of the mutated Maraba virus envelope protein has better stability in serum, and can be used for preparing a novel lentiviral vector of the mutated Maraba virus envelope. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

The invention discloses a < 19 > F MRI (Magnetic Resonance Imaging) composite nano contrast agent based on a targeting artificial protein crown as well as a preparation method and application thereof. According to the invention, folic acid is modified on plasma protein, and the modified plasma protein has folic acid receptor mediated specific targeting and selective tumor cell uptake by utilizing the overexpression characteristic of a folic acid receptor (FR) on the surface of a cancer cell. Meanwhile, by taking 20-fluoro-15-crown-5-ether as a magnetic resonance active molecule, packaging by using polylactic acid-glycolic acid, and synthesizing PLGA-PFCE nano-particles as the < 19 > F MRI nano contrast agent. The PLGA-PFCE nanoparticles and the modified plasma protein are co-incubated in vitro, an artificial protein crown is formed on the surface of the PLGA-PFCE nanoparticles, and the obtained 1PLGA-PFCE nanoparticle-targeting artificial protein crown compound directly realizes targeting to tumors through targeting small molecules on the surface of the protein crown; moreover, the characteristic that the targeting effect is reduced due to the fact that a common nano material adsorbs a protein crown after entering a living body can be overcome, and the signal intensity of < 19 > F MRI tumor in-situ imaging can be improved after the nano material is enriched to the tumor through intravenous injection.

The application belongs to the technical field of biological medicine, and particularly relates to synthesis of artificial immunoglobulin and application thereof in medicine. LYS and PD-L1 LYS / Plus is obtained through two-step mild self-assembly. The artificial immunoglobulin (IgPbeta) targeting PD-L1 obtained by the application can effectively degrade PD-L1 in cytoplasm, cell membrane and exosome of tumors in vitro and in vivo, while maintaining high tumor specificity and biological safety. The medicine including the substance prepared by the synthesis method of the application is not only effective in degrading tumor PD-L1 and realizing long-term remission of COAD and SKCM, but also avoids immune-related adverse events (IrAES), and further enables us to develop artificial protein medicine for regulating cell membrane and cytoplasm protein content through polypeptide foldamer.

[Problem] To provide a novel artificial protein catalyst that enables the protection of a catalyst from substances in vivo and has potential usefulness in therapeutic in vivo synthetic chemistry.[Solution] Provided is a complex of a protein and a catalyst selected from a metal catalyst or organic catalyst. In the complex according to the present invention, the protein is a protein having a hydrophobic pocket in the three-dimensional structure thereof, and the catalyst is housed in the hydrophobic pocket so that the catalyst is not or substantially not exposed to a hydrophilic environment.

The invention discloses recombinant escherichia coli with high yield of cyanidin-3-O-glucoside as well as a construction method and application of the recombinant escherichia coli. The method comprises the following steps: by taking escherichia coli BL21 (DE3) engineering bacteria as a host, integrating flavanonol 4-reductase, anthocyanin synthetase and flavonoid 3-O-glucosyltransferase from different sources onto a plasmid vector pRSFDuet, and constructing to obtain a chassis cell for producing C3G; meanwhile, glutathione transferase is overexpressed, dissolution-promoting tag small ubiquitin-like modified protein is added, FaDFR is modified through enzyme engineering, FaDFR catalytic efficiency is improved through artificial protein cage space combination pathway enzyme, key precursor UDP-glucose is synthesized in an in-situ intensified mode and cofactor engineering, the cell factory for efficiently synthesizing C3G is constructed based on the combination strategy, the yield of C3G is increased, and the method has the advantages that the method is simple and convenient to operate, and the cost is low. The titer reaches 797.20 mg / L. The method provided by the invention has the characteristics of simplicity, economy and eco-friendliness.

Micellar solutions comprising isolated non-human beta-casein and isolated non-human kappa-casein and substantially free of alpha S-casein artificial casein micelles, including methods of making the same, methods of coagulating the same, and compositions comprising the same; a method of preparing a curd composition from kappa-casein (whether phosphorylated, dephosphorylated or non-phosphorylated) with or without beta-casein (whether phosphorylated, dephosphorylated or non-phosphorylated) for use in the manufacture of downstream derivative products, such as cheese having functional characteristics comparable to equivalent products produced from milk; casein and protein emulsions of non-animal origin, curd compositions and cheese products and methods of producing the same; and a method of treating non-micellar casein to form a Parefirata style cheese product, such as a mozzarella style cheese product, comprising treating dephosphorylated casein or caseinate with a transglutaminase, in combination with oil or fat to form an emulsion useful for forming a cheese product, and treating non-micellar casein to form a Parefirata style cheese product, such as a mozzarella style cheese product. The cheese products may be processed using an acid-induced or chymosin-induced coagulation, such as acid-induced or chymosin-induced coagulation, and using standard cheese processing steps to produce different styles of cheese products.

The present invention relates to a synthetic peptide comprising, from the N-terminus to the C-terminus, the following elements: a) a first cell-penetrating peptide or a functional fragment or derivative thereof, or a bioactive variant, and b) a second peptide having agonist activity for the OR1 and OR2 receptors or a functional fragment or derivative thereof, or a bioactive variant.

According to the photo-thermal hydrogel drug carrier as well as the preparation method and the application thereof, artificial protein is prepared by designing a recombinant artificial protein sequence, so that the artificial protein has a good temperature response function, and a photo-thermal agent can be linked with a protein peptide chain, so that the photo-thermal hydrogel drug carrier which has the temperature response function and can be used for preparing the photo-thermal hydrogel drug carrier is obtained. The photo-thermal hydrogel which can be firmly combined with a photo-thermal agent gold nanorod can achieve synchronous carrying of macromolecular drugs and small molecular drugs and drug release of temperature response, has good biocompatibility and wide application potential, can achieve treatment of in-situ / far-end tumors of mice, and can also be applied to photo-thermal sterilization.

A block copolymer or the like, having: a first segment containing a protein structure; and one or more second segments containing a molecular group having a plasticizing function for the protein structure and bound to the first segment, in the block copolymer, the protein structure is a protein structure containing a main sequence, and a hydrophobic tag bound to the N-terminal and C-terminal of the main sequence, and having at least two reactive points that react with a compound having the second segment and a reactive group, the reactive point closest to the N-terminal side among the reactive points is present within the hydrophobic tag on the N-terminal side, or is NH2 as the N-terminal of the protein structure, or is present within the main sequence, the reactive point closest to the C-terminal side among the reactive points is present within the hydrophobic tag on the C-terminal side, or is present within 9 residues from the C-terminal of the main sequence.

The present disclosure relates to a virtual reality interaction device and method based on bimanual gestures for artificial protein skeleton design, the device and the method detecting bimanual gestures of a user gripping the same virtual axis in a space, and generating a protein secondary structure corresponding to the bimanual gestures along the virtual axis in the space. In the disclosure, the protein secondary structure can include at least one from among an alpha-helix, a beta-strand and a loop. In various embodiments, the bimanual gestures can include at least one from among a grab gesture, a closed pinch gesture and an open pinch gesture.

This block copolymer has a first segment containing a protein structure, and one or more second segments containing a molecular group that has a function of plasticizing the protein structure and is bonded to the first segment. The protein structure includes a main sequence and hydrophobic tags bonded to the N-terminus and the C-terminus of the main sequence, and has at least two points of reaction for reacting with the second segment and a compound having a reactive group. Among the points of reaction, the point of reaction that is on the most N-terminus side: is present in the hydrophobic tag on the N-terminus side; is the NH2 which is the N-terminus of the protein structure; or is present in the main sequence. Among the points of reaction, the point of reaction on the most C-terminus side is present in the hydrophobic tag on the C-terminus side or is present within 9 residues from the C-terminus of the main sequence.

The invention provides imitation protein particles and a preparation method thereof, and belongs to the technical field of nano materials. A double bond on a C chain segment in the biomimetic protein particle provided by the invention can be connected with a positive drug or a fluorophore through click chemistry, and a carboxyl group can be connected with a targeting peptide, a positive drug containing a hydroxyl group or an amino group and the like through DCC coupling, so that the magnetic biomimetic protein particle carrying drug molecules, the fluorophore and the targeting peptide is obtained, the hydrophilic chain segment A enables the biomimetic particle to be delivered in a living body, the hydrophilic chain segment B has magnetism and can penetrate some tissue fluid segments with resistance so as to enter parts where conventional drugs cannot enter for treatment, meanwhile, the targeting peptide can enable the biomimetic particle to be combined with in-vivo protein, so that the biomimetic particle can enter the living body more easily, and the biomimetic particle can be used for treating the tumor. The accumulation concentration of the medicine in a diseased region is effectively improved, and the curative effect is improved; the mimic protein particles are small in size, high in safety to human bodies and small in toxic and side effects.

The present invention discloses the use of cuprous ferrite as an artificial protease, which is prepared by a simple hydrothermal method. The artificial protease of the present invention not only has a simple synthesis method, but also can efficiently hydrolyze protein with a fast hydrolysis speed and a wide pH range.

The present invention relates to the technical field of protein synthesis, e.g. of complex proteins and human proteins. It provides a new artificial eukaryotic cell-free translation system suitable for the incorporation of at least one or more unnatural amino acids (uaa) in predetermined positions of an artificial protein. A method for a cell-free manufacture of the artificial protein comprising one or more uaas in predetermined positions of the artificial protein is also provided. The system, a cell-free system, a kit and nucleic acid constructs are provided and are for use in said method. The advantage of the present invention is that the method allows manipulation of any desired protein by incorporation of one or more uaas. Further, the method and / or the achieved artificial protein is suitable to be combined with a linking reaction to link the artificial protein, e.g. to virus like particles or another molecule.

The present invention discloses a reliable protease activity biosensor for determining the cleavage of a protease recognition site that can be viewed by FRET, fluorescence change or by SDS-PAGE electrophoresis. This biosensor consists of a globular domain, a flexible connector with a variable protease recognition / cleavage area and a second globular domain. The proposed invention can be useful for detecting proteases and assessing the activity thereof, as well as finding novel protease inhibitors or monitoring the efficiency of therapeutic agents in patients undergoing treatment. The proposed biosensor is an engineered protein from the rational engineering of proteins which makes this molecule unique and not available in nature.

Described herein is a method for generating an artificial protein, comprising: training an immunogenicity conditioner to predict one or more lymphocyte receptor sequences that recognize one or more target molecules; using a gradient computed using one or more parameters of the immunogenicity conditioner to guide a generative process of protein design, wherein the gradient is computed to guide the design of the artificial protein such that the artificial protein is recognized by a target set of the one or more of lymphocyte receptor sequences; testing the recognition of the resulting artificial protein by one or more of the lymphocyte receptor sequences using an experimental assay.

The present invention relates to a method for enhancing the folding of disulfide-bonded proteins in E. coli. The method for activating a disulfide-bonded protein in E coli according to the present invention enables a disulfide bond-requiring protein to be stably folded and activated in E coli without a separate refolding process by utilizing an artificial protein endowed with redox capability. Accordingly, the method allows for the efficient production of disulfide-bonded proteins, which have been difficult to express in E coli in the past, thereby providing advantages for large-scale industrial application and pharmaceutical development involving disulfide-bonded proteins.

The application artificially designs and creates a functional module SyKerMb with high efficient degradation of poultry feather waste and synthesis of new heme protein by using synthetic biology method. The application constructs a recombinant vector of the functional module, and assembles and expresses the same in a chassis microbial cell Escherichia coli. Experiments prove that the engineered strain integrated with the conversion functional module has the biological synthesis capacity of degrading animal waste feather and efficiently synthesizing artificial heme protein, and can be used in artificial protein preparation and future artificial food and other related industrial production.

Disclosed in the present invention are a method for designing a fusion protein for selective knockdown or inhibition of a mutant of a protein, and a use thereof. The method comprises the following step: linking a ligand to a ubiquitin ligase to obtain a fusion protein, wherein the ligand has a high affinity for the activated form of a target protein and a low affinity for the inactivated form of the target protein. An artificial protein or a small molecule drug designed by said method targets only mutant-type proteins that lead to diseased tissue, and is ineffective on wild-type proteins in normal tissue, thereby achieving safe treatment.

The present invention discloses a controllable protein recruitment system based on artificial protein cages and a construction method thereof, belonging to the technical fields of genetic engineering and bioengineering. In the present invention, Mi3 is used as a scaffold protein, and an FKBP short peptide is connected to the scaffold protein by gene fusion, and the outer surface of Mi3 is modified to obtain a Mi3 that responds to rapamycin stimulation chem ; meanwhile, by utilizing the property that the small molecule rapamycin mediates the non-covalent heterodimerization of FK506-binding protein (FKBP) and FRB, in the case of adding rapamycin, the recruitment of cargo proteins with FRB tags on Mi3 chem is realized, and good recruitment effects are achieved in both extracellular and intracellularly constructed protein cages. The present invention realizes a controllable recruitment process for target proteins, providing new ideas and new ways for efficient production.

The present invention provides a protein including an amino acid sequence that has at least 80% identity with the amino acid sequence represented by SEQ ID NO: 7 or 8. The protein has suppressed silicic acid transport activity.